Bio Plus Co

Bio Plus Co Rule of 40

The Rule of 40 of Bio Plus Co (099430.KQ) as of Oct 22, 2026 is 53.38 %. In the previous year, Rule of 40 was 37.74 % — a change of 41.44% (higher).

Rule of 40

53.38 %

YoY

41.44%

Last updated:

Rule of 40 of Bio Plus Co is 2025 53.38 % . Rule of 40 of Bio Plus Co was 2024 37.74 % . It decreases by 41.44% higher compared to the previous year.

The Bio Plus Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2019
94.16 KRW
Jan 1, 2020
93.75 KRW
Jan 1, 2021
98.09 KRW
Jan 1, 2022
96.09 KRW
Jan 1, 2023
57.78 KRW
Jan 1, 2024
37.74 KRW
Jan 1, 2025
53.38 KRW
The Bio Plus Co Rule of 40 history
YEARRule of 40YoY
53.38 %+41.44%
37.74 %-34.68%
57.78 %-39.87%
96.09 %-2.05%
98.09 %+4.63%
93.75 %-0.43%
94.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Rule of 40 of Bio Plus Co is 53.38 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Bio Plus Co

All Key Metrics — Bio Plus Co